6、总 结
高血压的基因治疗研究已经取得了瞩目的成就，但大部分研究成果还处于临床转化应用前期阶段，尚有许多问题需要解决。高血压发病涉及多基因、多因素，尽管目前已经发现了许多与高血压发病相关的基因变异位点，但要通过基因治疗技术从根本上治疗高血压，还需要开展更多动物实验和临床研究，进一步深入了解高血压相关基因的调控机制，为基因治疗安全转向临床最终应用提供科学依据。
参考文献：
[1] 陈伟伟，高润霖，刘力生，等.中国心血管病报告2015摘要.中国循环杂志, 2016, 31(6):521-528.
[2] 邹玉宝，孙筱璐，王继征，单基因致病型高血压[J].中华医学前沿杂志.2016,8(5):16-22.
[3] 杜婷婷，张子波. 原发性高血压遗传流行病学研究现状[J]. 国际遗传学杂志, 2009, 32:24.
[4] 杨国红，周欣，姜铁民等. 高血压发病机制的基因学研究进展[J]. 武警医学, 2013, 24:985-988.
[5] Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension[J], Circ Res, 2015,(116): 937-959.
[6] Rossi GP, Ceolotto G, Caroccia B, et al. Genetic screening in arterial hypertension[J]. Nat Rev Endocrinol, 2017. doi: 10.1038/nrendo. 2016,196.[Epub ahead of print]
[7] Hao Q, Dong X, Chen X, et al. ACE2 inhibits angiotensin II-induced abdominal aortic aneurysm in mice[J]. Hum Gene Ther, 2017. doi: 10.1089/hum. 2016,144. [Epub ahead of print]
[8] Basu R, Poglitsch M, Yogasundaram H, et al. Roles of angiotensin peptides and recombinant human ACE2 in heart failure[J]. J Am Coll Cardiol, 2017,69(7):805-819.
[9] Chen S. Essential hypertension: perspectives and future directions[J]. J Hypertens, 2012(30) :42-45.
[10] 张颖捷, 杜万红. 高血压治疗新进展[ J ] . 中国老年学杂志, 2015,35(7):4084-4087.
[11] 红梅, 付军, 高血压基因治疗回顾与展望[J]. 实用医学杂志, 2010, 26(7):1250-1252.
[12] Schreiber CA, Holditch SJ, Generous A, et al. Sustained ELABELA gene therapy in high salt-induced hypertensive rats[J]. Curr Gene Ther, 2016. Nov 21. [Epub ahead of print]
[13] Lambert DW, Lambert LA, Clarke NE, et al. Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421[J]. Clinical science, 2014,127:243-249.
[14] Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction[J]. Circulation, 2010,122:717-728.
[15] Patel VB, Zhong JC, Grant MB, et al. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure[J]. Circ Res, 2016,118(8):1313-1326.
